| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Feb, 2026 | Feb, 2026 | Feb, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -27,290 | -24,750 | 0 | 0 | 0 |
| Net Income Growth | -10.26% | unch | unch | unch | unch |
Actuate Therapeutics Inc
(ACTU)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Actuate Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers. The company's lead product includes elraglusib. Actuate Therapeutics Inc. is based in FORT WORTH, Texas.
Fiscal Year End Date: 12/31